Greater China News
XtalPi Inc. Unveils “XtalPi Intelligent Automation” and Announces New Automation Facility in Shanghai
XtalPi Inc. (XtalPi), a leading technology platform company renowned for melding physics-based computation, artificial intelligence (AI), and robotics to advance the discovery and evolution of groundbreaking medicines and innovative materials, unveiled its newest brand, XtalPi Intelligent Automation, at the inaugural Intelligent Automation Forum on August 25th, 2023, in Shanghai, China.
Mindray Introduces Innovative Upgrades to A Series Anaesthesia Systems for Enhanced Patient Safety and Efficiency
Mindray (SZSE: 300760), a global leader in providing advanced medical device solutions, has unveiled upgrades to its A7 and A5 anaesthesia systems under the A Series Anaesthesia.
InnoCare Releases 2023 Interim Results and Business Highlights
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023.
Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF
Akeso (9926. HK) released its 2023 interim performance: the Company achieved financial profitability for the first time in the first half of 2023
Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure
Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023.
Zylox-Tonbridge Reveals 2023 Interim Financial Results: Revenue Surges 50.7% YOY to 230 Million Yuan, Gross Profit Climbs to 171 Million Yuan
Zylox-Tonbridge released its financial results for the first half of 2023.
Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability
Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0%
Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress
Recbio (02179.HK) announced its latest progress and interim results for 2023.
Harbour BioMed Announces 2023 Interim Results
Harbour BioMed announced its interim results for the six months ended June 30, 2023.
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients were presented in a late-breaking science session at the European Society of Cardiology (ESC) Congress 2023 and simultaneously published in a JAMA Cardiology paper titled, “Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy.”
